Connecticut House Bill HB05295

Connecticut 2018 Regular Session

• Introduced: 2/28/18
• Refer: 2/28/18

Caption

An Act Concerning The Certification Of Pharmaceutical Sales Representatives.

Impact

If enacted, HB 05295 would bring significant changes to how pharmaceutical sales representatives operate within the state. By instituting certification, the bill seeks to ensure that these representatives possess a certain level of knowledge and understanding regarding the products they are promoting. This could lead to improved communication between sales representatives and health care providers, ultimately benefiting patient care by ensuring that providers receive accurate and reliable information.

Summary

House Bill 05295 is aimed at establishing a certification requirement for pharmaceutical sales representatives in the state. The bill specifies that any individual employed as a pharmaceutical sales representative must be certified through a program developed by either The University of Connecticut School of Pharmacy or the University of Saint Joseph School of Pharmacy. This measure is intended to enhance the professionalism and credibility of individuals marketing pharmaceuticals to health care providers, promoting better standards within the industry.

Contention

While the bill has potential benefits in terms of professional standards and care quality, there are also concerns about the implications of such regulation. Critics might argue that introducing certification requires additional time and money from sales representatives, which could limit entry into the profession. Furthermore, the effectiveness of such certifications in actually improving the quality of information shared with health care providers could also be called into question. Balancing the need for regulation with the potential for economic impact on local sales forces will be a notable point of contention.